These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 11983246)
1. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Mascola JR Vaccine; 2002 May; 20(15):1922-5. PubMed ID: 11983246 [TBL] [Abstract][Full Text] [Related]
2. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111 [TBL] [Abstract][Full Text] [Related]
6. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297 [TBL] [Abstract][Full Text] [Related]
7. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630 [TBL] [Abstract][Full Text] [Related]
8. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779 [TBL] [Abstract][Full Text] [Related]
9. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419 [TBL] [Abstract][Full Text] [Related]
10. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411 [TBL] [Abstract][Full Text] [Related]
11. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869 [TBL] [Abstract][Full Text] [Related]
12. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745 [TBL] [Abstract][Full Text] [Related]